Literature DB >> 26679822

Canine bone marrow cytological examination, classification and reference values: A retrospective study of 295 cases.

Vanessa Turinelli1, Alessandra Gavazza2, Graham Stock3, Corinne Fournel-Fleury4.   

Abstract

Cytologic assessment of bone marrow with knowledge of the hemogram represents an effective method to investigate hemic tissue and its function. To determine the spectrum and prevalence of canine bone marrow disorders over a 2 year period in a diagnostic laboratory setting achieved through a standard approach to cytologic bone marrow assessment. A retrospective study of bone marrow fine needle aspirates sample preparations, blood smears, hemogram data and case records. Of the 295 bone marrow samples evaluated, 90 (30.5%) were nondiagnostic samples. Of the remaining samples, 25.1% were classified as hyperplasia of which most were granulocytic hyperplasia (58.1% of the total hyperplasia), 19.3% had no cytological abnormalities, 12.9% had malignant hemopathy and 7.8% had hypo-aplastic conditions. Only a small proportion of cases involved dysplasia (1.7%) and metastatic disease was detected in only one case (0.3%). Reference values of nucleated cells and the M/E ratio were calculated for normal and erythroid and granulocytic hyperplastic bone marrow. This study provides the spectrum and the prevalence of canine bone marrow disorders as well as a differential bone marrow cell counting and determination of reference intervals for diseases.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bone marrow; Cytological examination; Dogs; Reference intervals

Mesh:

Year:  2015        PMID: 26679822     DOI: 10.1016/j.rvsc.2015.10.008

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  1 in total

1.  Clinical and clinicopathological features and outcomes of Miniature Dachshunds with bone marrow disorders.

Authors:  Akiyoshi Tani; Hirotaka Tomiyasu; Aki Ohmi; Koichi Ohno; Hajime Tsujimoto
Journal:  J Vet Med Sci       Date:  2020-04-17       Impact factor: 1.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.